China SXT Pharmaceuticals Inc
SXTC1.610USD
+0.070+4.55%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
22.16MMarket Cap
LossP/E TTM
More Details of China SXT Pharmaceuticals Inc Company
China SXT Pharmaceuticals Inc is a holding company principally engaged in the research, development, manufacture, marketing and sales of Traditional Chinese Medicine Pieces (TCMP). TCMP is a type of Chinese Traditional Medicine (TCM) products. The Company sells three types of TCMP products: Advanced TCMP, Fine TCMP and Regular TCMP. The Company sells its products under the brand Suxuantang. The Company mainly operates its businesses in the domestic market.
China SXT Pharmaceuticals Inc Info
Ticker SymbolSXTC
Company nameChina SXT Pharmaceuticals Inc
IPO dateJan 04, 2019
CEOBeng (Lim Sze)
Number of employees75
Security typeOrdinary Share
Fiscal year-endJan 04
Address178 Taidong Road North
CityTAIZHOU
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryChina
Postal code225300
Phone8652386298290
Websitehttps://www.sxtchina.com/
Ticker SymbolSXTC
IPO dateJan 04, 2019
CEOBeng (Lim Sze)
Company Executives of China SXT Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Feng Zhou
Mr. Feng Zhou
Co-Chief Executive Officer, Director
Co-Chief Executive Officer, Director
532.00
-94.18%
Mr. Lim Sze (Simon) Beng
Mr. Lim Sze (Simon) Beng
Co-Chief Executive Officer
Co-Chief Executive Officer
--
--
Mr. Xiaodong Pan
Mr. Xiaodong Pan
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Jun Zheng
Mr. Jun Zheng
Director
Director
--
--
Mr. Xiaodong Ji
Mr. Xiaodong Ji
Independent Director
Independent Director
--
--
Mr. Tong Liu
Mr. Tong Liu
Independent Director
Independent Director
--
--
Mr. Lip Chee Yong
Mr. Lip Chee Yong
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Feng Zhou
Mr. Feng Zhou
Co-Chief Executive Officer, Director
Co-Chief Executive Officer, Director
532.00
-94.18%
Mr. Lim Sze (Simon) Beng
Mr. Lim Sze (Simon) Beng
Co-Chief Executive Officer
Co-Chief Executive Officer
--
--
Mr. Xiaodong Pan
Mr. Xiaodong Pan
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Jun Zheng
Mr. Jun Zheng
Director
Director
--
--
Mr. Xiaodong Ji
Mr. Xiaodong Ji
Independent Director
Independent Director
--
--
Mr. Tong Liu
Mr. Tong Liu
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Regular TCMP
1.44M
82.86%
Advanced TCMP
258.42K
14.84%
Others
40.02K
2.30%
By RegionUSD
Name
Revenue
Proportion
People's Republic of China
1.74M
100.00%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Regular TCMP
1.44M
82.86%
Advanced TCMP
258.42K
14.84%
Others
40.02K
2.30%
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Foong Soon Hong (Randy)
9.13%
Seng (Tan Soo)
8.96%
Tan (Cheng Guan)
8.79%
Ching (Choon Hwa)
8.45%
Invesco Capital Management LLC
0.08%
Other
64.60%
Shareholders
Shareholders
Proportion
Foong Soon Hong (Randy)
9.13%
Seng (Tan Soo)
8.96%
Tan (Cheng Guan)
8.79%
Ching (Choon Hwa)
8.45%
Invesco Capital Management LLC
0.08%
Other
64.60%
Shareholder Types
Shareholders
Proportion
Individual Investor
35.32%
Investment Advisor
0.10%
Hedge Fund
0.10%
Investment Advisor/Hedge Fund
0.05%
Research Firm
0.03%
Other
64.41%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
18
220.19K
0.19%
+206.13K
2025Q2
20
28.22K
2.38%
-47.81K
2025Q1
20
28.22K
0.02%
-47.80K
2024Q4
22
74.93K
15.02%
+42.94K
2024Q3
24
33.98K
13.64%
+10.51K
2024Q2
21
35.50K
15.27%
+22.93K
2024Q1
24
15.92K
23.88%
+2.99K
2023Q4
23
15.02K
23.00%
+2.57K
2023Q3
23
16.29K
24.79%
+5.61K
2023Q2
20
14.62K
58.36%
+11.76K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Foong Soon Hong (Randy)
10.59M
9.13%
+10.59M
--
Jul 29, 2025
Seng (Tan Soo)
10.39M
8.96%
+10.39M
--
Jul 29, 2025
Tan (Cheng Guan)
10.20M
8.79%
+10.20M
--
Jul 29, 2025
Ching (Choon Hwa)
9.80M
8.45%
+9.80M
--
Jul 29, 2025
Invesco Capital Management LLC
89.66K
0.08%
+89.66K
--
Sep 30, 2025
Citadel Advisors LLC
--
0%
-2.01K
-100.00%
Sep 30, 2024
Virtu Americas LLC
13.97K
0.01%
+13.97K
--
Jun 30, 2025
HRT Financial LP
--
0%
-243.00
-100.00%
Dec 31, 2023
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco Golden Dragon China ETF
0.08%
Invesco Golden Dragon China ETF
Proportion0.08%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Feb 21, 2025
Merger
8→1
Feb 21, 2025
Merger
8→1
Feb 21, 2025
Merger
8→1
Feb 21, 2025
Merger
8→1
Oct 04, 2023
Merger
25→1
Oct 04, 2023
Merger
25→1
Date
Type
Ratio
Feb 21, 2025
Merger
8→1
Feb 21, 2025
Merger
8→1
Feb 21, 2025
Merger
8→1
Feb 21, 2025
Merger
8→1
Oct 04, 2023
Merger
25→1
Oct 04, 2023
Merger
25→1
Oct 04, 2023
Merger
25→1
Oct 04, 2023
Merger
25→1
May 18, 2022
Merger
20→1
May 18, 2022
Merger
20→1
View more
FAQs
Who are the top five shareholders of China SXT Pharmaceuticals Inc?
The top five shareholders of China SXT Pharmaceuticals Inc are:
Foong Soon Hong (Randy) holds 10.59M shares, accounting for 9.13% of the total shares.
Seng (Tan Soo) holds 10.39M shares, accounting for 8.96% of the total shares.
Tan (Cheng Guan) holds 10.20M shares, accounting for 8.79% of the total shares.
Ching (Choon Hwa) holds 9.80M shares, accounting for 8.45% of the total shares.
Invesco Capital Management LLC holds 89.66K shares, accounting for 0.08% of the total shares.
Foong Soon Hong (Randy) holds 10.59M shares, accounting for 9.13% of the total shares.
Seng (Tan Soo) holds 10.39M shares, accounting for 8.96% of the total shares.
Tan (Cheng Guan) holds 10.20M shares, accounting for 8.79% of the total shares.
Ching (Choon Hwa) holds 9.80M shares, accounting for 8.45% of the total shares.
Invesco Capital Management LLC holds 89.66K shares, accounting for 0.08% of the total shares.
What are the top three shareholder types of China SXT Pharmaceuticals Inc?
The top three shareholder types of China SXT Pharmaceuticals Inc are:
Foong Soon Hong (Randy)
Seng (Tan Soo)
Tan (Cheng Guan)
Foong Soon Hong (Randy)
Seng (Tan Soo)
Tan (Cheng Guan)
How many institutions hold shares of China SXT Pharmaceuticals Inc (SXTC)?
As of 2025Q3, 18 institutions hold shares of China SXT Pharmaceuticals Inc, with a combined market value of approximately 220.19K, accounting for 0.19% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -2.19%.
What is the biggest source of revenue for China SXT Pharmaceuticals Inc?
In FY2025, the Regular TCMP business generated the highest revenue for China SXT Pharmaceuticals Inc, amounting to 1.44M and accounting for 82.86% of total revenue.
